基于顾客价值的成本管理——价值链成本分析

在当今竞争激烈的市场环境中,企业要获得竞争优势,就要面向顾客价值,本文论述了企业可以通过核算产品性质成本从而将成本分配到价值链,为成本降低开拓了空间,而价值链分析有助于企业的战略决策,从而获得竞争优势。     

物流市场管制的经济分析

从管制理论的角度分析了物流市场失灵，从成本-效益角度进行物流市场管制的经济分析，以及物流市场管制中需要注意的问题，最后阐述了建立完善的物流市场经济体制需要适当的物流市场管制，才能节约交易费用，提高物流市场的整体运行效益。     

基于QFD的物流战略规划

分析了应用质量功能展开进行物流战略规划的意义，将物流战略规划分解为系统收集基础信息，推演，评价，整合物流战略目标四个步骤，并基于QFD方法分别进行了阐述。     

会计信息化发展及其影响

在信息化时代,会计信息化应该面向国民经济和社会信息化,会计信息化的主要任务是会计职业判断的智能化,在此基础上,将社会经济的监督权与会计信息的生产整合,创新一种新的会计信息生产方式。会计信息化对会计理论与实践产生了巨大的冲击与革新。     

物流中心选址的影响因素分析及案例

运用现代物流及城市规划原理，对物流中心选址的原则及影响因素进行系统的分析研究，并在此基础上提出了物流中心选址的方法及注意事项。最后用“廊坊国际物流中心选址”案例对选址方法进行验证。     

上市公司控制权转移的财富效应分析

上市公司控制权的转移会改变投资者对目标公司的预期,从而引起目标公司股价的变化,进而使得目标公司股东的财富发生变化。本文采用事件研究法,分行业对2002年我国资本市场上第一大股东发生变更的目标方公司股东财富进行了实证研究。结果表明:对于整个资本市场而言,控制权转移能为目标公司带来显著的财富增加;而对于不同行业控制权转移的财富效应存在着较大的差别,只有原材料企业在公告日前可以获得显著的正财富效应,而工业企业和消费企业的财富效应并不明显。     

从产业经济学角度浅论我国物流业的发展

从产业经济学的基本理论入手,探讨如何正确认识我国的物流产业及其在国民经济中的地位,并结合我国实际,研究和评价我国物流产业的总体发展水平,分析物流产业的发展对策。     

独立审计质量的经济学分析

本文通过对审计质量的经济学分析,提出高质量的审计是增进契约效率的内生需要,中小股东和上市公司之间的“隐性契约”是推动审计质量提高的重要力量。我国特有的经济环境背景,决定了审计质量的提高存在着制度性障碍,审计质量是各方利益相互均衡的结果。     

Towards a kernel theory of external knowledge integration for high-tech firms: Exploring a failed theory test

Designing information systems (ISs) requires a thorough understanding of the organizational knowledge processes in which these systems are used. Although much is known about internal organizational knowledge processes, the understanding of external knowledge processes is less developed. Hence, this paper reflects an attempt to operationalize and test a model of the process of external knowledge integration (EKI), consisting of an identification, acquisition, and utilization stage. We utilize high-technology based firms from a variety of high-tech categories including nanotechnology based firms since these firms have critical knowledge integration needs. The results of an international survey, with responses of 317 high-tech companies, suggest that not these three EKI-stages, but four organizational effectiveness functions (goal attainment, pattern maintenance, adaptation, and integration) account for most variation in responses. These findings seem to imply that ISs that are to support the EKI-process should be designed according to organizational effectiveness functions rather than to EKI-stages. It is proposed that each organizational effectiveness function imposes different requirements on ISs because users interact differently with IS in each function.     

Cost effectiveness of benralizumab for severe,uncontrolled oral corticosteroid–dependent asthma in Sweden

Abstract

Aim: We investigated cost effectiveness of benralizumab vs. standard of care (SOC) plus oral corticosteroids (OCS) for patients with severe, eosinophilic OCS-dependent asthma in Sweden.

Materials and methods: A three-state, cohort-based Markov model of data from three Phase III benralizumab clinical trials (ZONDA [NCT02075255], SIROCCO [NCT01928771], and CALIMA [NCT01914757]) was used to assess the incremental cost-effectiveness ratio of benralizumab vs. SOC plus OCS. Health outcomes were estimated in terms of quality-adjusted life-years (QALYs). The model included costs and disutilities associated with extrapolated OCS-related adverse events. Patients with severe asthma were defined as those receiving OCS ≥5?mg/day.

Results: Benralizumab demonstrated a cost-effectiveness ratio vs. SOC plus OCS of 2018 Swedish Kronor (SEK) 366,855 (€34,127) per QALY gained, based on increases of 1.33 QALYs and SEK 488,742 (€45,344) per patient. Benralizumab treatment costs contributed most to incremental costs. The probability of benralizumab’s being cost-effective with willingness-to-pay (WTP) thresholds between SEK 429,972 (€40,000) and SEK 752,452 (€70,000) ranged from 75% to 99%.

Limitations: Potential limitations of these analyses include the use of combined data from three different clinical trials, a one-way sensitivity analysis that did not include mortality and transition estimates, and Observational & Pragmatic Research Institute (OPRI) data from the UK as a proxy of the Swedish health care system.

Conclusions: The results of these analyses demonstrate that benralizumab has a high probability of being cost-effective compared with SOC plus OCS for a subgroup of patients with severe, eosinophilic asthma receiving regular OCS treatment and may support clinicians, payers and patients in making treatment decisions.